# Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

> **NCT02715882** · PHASE2 · UNKNOWN · sponsor: **BioLab 612 LLC** · enrollment: 40 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** CBLB502
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02715882
- **Lead sponsor:** BioLab 612 LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2017-02
- **Final completion:** 2017-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02715882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02715882, "Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02715882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*